CYP1A2 rs4886406: Understanding Your Genetic Metabolism
The rs4886406 variant is a genetic change located within the CYP1A2 gene, which plays a critical role in how the body processes various medications and compounds. This variant is studied in the field of pharmacogenomics to understand how inherited differences may influence individual drug metabolism and therapeutic outcomes.
What each genotype means
Typical metabolic activity
This genotype represents the most common genetic configuration for this specific variant. While research into this specific marker is ongoing, it is generally considered to have a neutral impact on the function of the CYP1A2 enzyme. Please discuss any concerns regarding medication metabolism or dosing with your clinician or pharmacist.
This is the most frequently observed genotype across most global populations.
Variable metabolic activity
Carrying one copy of the C allele may influence how your body processes certain substances metabolized by the CYP1A2 enzyme, though evidence for this specific variant remains limited. Because individual drug response is influenced by many factors including other genetic markers, diet, and lifestyle, this result should not be used to make clinical decisions. Always consult with your healthcare provider regarding your specific medication needs.
This heterozygous genotype is found at varying frequencies depending on ancestral background, appearing in a significant portion of the population.
Potential metabolic variation
This genotype indicates you carry two copies of the C allele for this variant. Current scientific literature is still evaluating the specific functional consequences of this marker on enzyme activity, and findings can be mixed or ancestry-specific. This information is for educational purposes and should not be used to alter any prescribed treatments; please discuss your pharmacogenomic profile with your doctor.
This genotype is less common than the AA or AC configurations in many populations, with frequency varying significantly by geographic and ancestral origin.
What is the rs4886406 Variant?
The rs4886406 variant is a single nucleotide polymorphism (SNP) situated within the CYP1A2 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is located in a region of the genome that influences the expression or function of the CYP1A2 enzyme. Because it sits within a gene responsible for drug metabolism, researchers monitor this site to determine if it contributes to the observed inter-individual differences in how people process drugs. While many SNPs exist throughout the human genome, those located in pharmacogenes like CYP1A2 are of particular interest because they may help explain why two people can take the same dose of a medication but experience different levels of effectiveness or side effects.
The Role of the CYP1A2 Gene
The CYP1A2 gene provides instructions for making an enzyme called cytochrome P450 1A2. This enzyme is primarily found in the liver and is responsible for breaking down, or metabolizing, a wide variety of substances, including caffeine, certain medications, and environmental toxins. By converting these substances into forms that the body can easily eliminate, CYP1A2 acts as a key component of the body's detoxification system. The activity level of this enzyme can vary significantly from person to person due to both genetic factors and environmental influences, such as smoking or diet. When genetic variants like rs4886406 are present, they may alter the efficiency of this enzyme, potentially leading to faster or slower clearance of drugs from the bloodstream. Understanding this gene is essential for the field of pharmacogenomics, which seeks to tailor medical treatments to an individual's unique genetic profile.
Research and Evidence Strength
The evidence linking rs4886406 to specific clinical outcomes is currently categorized as moderate. While the CYP1A2 gene is well-documented as a major metabolic pathway for many drugs, the specific functional impact of the rs4886406 variant is still being characterized in scientific literature. Research often focuses on how variants in this gene correlate with drug plasma concentrations or the risk of adverse reactions. However, because drug metabolism is a complex process influenced by multiple genes and environmental factors, it is difficult to isolate the effect of a single SNP. Current studies continue to investigate whether this variant serves as a reliable biomarker for predicting drug response. Because the evidence is evolving, it is important to view these findings as statistical associations rather than definitive predictors of how any one individual will respond to a specific medication.
Population Frequency and Variability
The frequency of the rs4886406 variant is known to be variable across different global populations. Genetic studies, such as those utilizing data from the 1000 Genomes Project, consistently show that the prevalence of specific alleles can differ significantly based on geographic ancestry. For instance, some variants in the CYP1A2 gene are common in European populations but rare in Asian or African populations, and vice versa. This population-specific distribution is a hallmark of pharmacogenomic research, highlighting why it is crucial to consider ancestry when interpreting genetic data. Because the frequency of rs4886406 is not uniform, the potential impact of this variant on drug metabolism may also vary depending on an individual's genetic background. Researchers use these frequency patterns to better understand the global landscape of drug-metabolizing enzymes.
What This Information Means for You
It is important to understand that having a particular genotype for rs4886406 does not constitute a medical diagnosis or a guarantee of how you will react to a medication. Pharmacogenomic information is intended to be used as one piece of a larger puzzle that includes your medical history, current health status, and other lifestyle factors. You cannot and should not use this information to make independent decisions about your prescription medications. If you are curious about how your genetics might influence your response to a drug, the best course of action is to discuss this with your clinician or a pharmacist. They are trained to interpret genetic data in the context of your overall health and can provide guidance on whether testing is appropriate or how to adjust your treatment plan safely if necessary.
How common is this variant?
The frequency of the rs4886406 variant is variable across different ancestral populations, with specific allele distributions often differing significantly between global groups.
Frequently asked questions
Can I use this genetic information to change my medication dose?
No, you should never change your medication dose based on genetic information alone. Always consult with your doctor or pharmacist before making any adjustments to your prescribed treatment.
Is rs4886406 the only variant that affects CYP1A2?
No, the CYP1A2 gene has many different variants that can influence its function. rs4886406 is just one of many SNPs that researchers study to understand how this gene works.
Does this variant mean I will have side effects from drugs?
Not necessarily. Genetic variants are only one factor that influences how you respond to drugs; other factors like age, diet, and other medications play a significant role as well.
Where can I get tested for this variant?
Genetic testing for pharmacogenomics is typically ordered by a healthcare provider if it is clinically relevant to your treatment. You should speak with your doctor if you are interested in learning more about your pharmacogenetic profile.
Sources & further reading
Educational information only, last refreshed 10/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4886406?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP1A2
This variant in the CYP1A2 gene influences the hepatic metabolism rate of caffeine and is a key marker for individual differences in caffeine clearance.
Intronic marker associated with CYP1A2 enzyme activity and caffeine metabolism rates.
Modulates CYP1A2 inducibility affecting the rate of caffeine metabolism and clearance.
Regulatory variant associated with CYP1A2 enzyme activity, influencing the rate of caffeine metabolism and habitual coffee consumption.
A common variant in the CYP1A2 gene associated with caffeine metabolism rates.
Located in intron 1 of CYP1A2, this variant modulates inducible enzyme activity, altering systemic caffeine clearance and individual susceptibility to caffeine-related blood pressure increases.